Eyepoint Pharmaceuticals (NASDAQ:EYPT) Price Target Cut to $1.00 by Analysts at Royal Bank Of Canada

Eyepoint Pharmaceuticals (NASDAQ:EYPT) had its price target dropped by Royal Bank Of Canada to $1.00 in a research report issued to clients and investors on Tuesday, Benzinga reports. The firm currently has a “sector perform” rating on the stock. Royal Bank Of Canada‘s price target points to a potential upside of 133.59% from the company’s previous close.

A number of other research firms also recently weighed in on EYPT. Mizuho reaffirmed a “neutral” rating and issued a $0.50 price target on shares of Eyepoint Pharmaceuticals in a research note on Tuesday. Cantor Fitzgerald downgraded shares of Eyepoint Pharmaceuticals from an “overweight” rating to a “neutral” rating in a research note on Monday, August 17th. Guggenheim downgraded shares of Eyepoint Pharmaceuticals from a “buy” rating to a “neutral” rating in a report on Monday. JPMorgan Chase & Co. restated an “underweight” rating on shares of Eyepoint Pharmaceuticals in a report on Tuesday. Finally, Chardan Capital downgraded shares of Eyepoint Pharmaceuticals from a “buy” rating to a “neutral” rating and set a $5.00 price target on the stock. in a report on Tuesday, August 18th. Two equities research analysts have rated the stock with a Buy rating, nine have given a Hold rating and two have given a Sell rating to the company. According to MarketBeat.com, Eyepoint Pharmaceuticals presently has a consensus rating of “Hold” and an average target price of $21.85.

Eyepoint Pharmaceuticals Stock Performance

Shares of NASDAQ EYPT traded down $0.00 during trading on Tuesday, hitting $0.43. The company had a trading volume of 12,440,354 shares, compared to its average volume of 3,481,274. The company has a market cap of $36.91 million, a P/E ratio of -0.11 and a beta of 1.67. Eyepoint Pharmaceuticals has a 52 week low of $0.39 and a 52 week high of $19.11. The business’s 50-day moving average is $4.25 and its 200 day moving average is $10.12.

Eyepoint Pharmaceuticals (NASDAQ:EYPT) last posted its quarterly earnings data on Wednesday, August 5th. The company reported ($1.09) EPS for the quarter, missing analysts’ consensus estimates of ($1.01) by ($0.08). The firm had revenue of $0.51 million during the quarter, compared to analyst estimates of $0.45 million. Eyepoint Pharmaceuticals had a negative return on equity of 135.81% and a negative net margin of 10,994.73%. On average, research analysts expect that Eyepoint Pharmaceuticals will post -3.51 EPS for the current year.

Institutional Investors Weigh In On Eyepoint Pharmaceuticals

Institutional investors have recently added to or reduced their stakes in the company. KBC Group NV bought a new position in Eyepoint Pharmaceuticals during the 1st quarter valued at about $29,000. Integrated Wealth Concepts LLC bought a new position in shares of Eyepoint Pharmaceuticals in the second quarter valued at approximately $72,000. Pictet Asset Management Holding SA bought a new position in shares of Eyepoint Pharmaceuticals in the first quarter valued at approximately $141,000. Engineers Gate Manager LP bought a new position in shares of Eyepoint Pharmaceuticals in the second quarter valued at approximately $161,000. Finally, Janney Montgomery Scott LLC raised its stake in shares of Eyepoint Pharmaceuticals by 14.8% in the first quarter. Janney Montgomery Scott LLC now owns 30,315 shares of the company’s stock valued at $391,000 after acquiring an additional 3,900 shares during the last quarter. 99.41% of the stock is owned by institutional investors and hedge funds.

Eyepoint Pharmaceuticals News Summary

Here are the key news stories impacting Eyepoint Pharmaceuticals this week:

• Positive Sentiment: HC Wainwright raised its Q3 2027 EPS forecast to $0.45 from a projected loss of $0.45, suggesting the analyst still sees a potential path to profitability in the longer term. However, the firm maintained a Neutral rating. HC Wainwright estimates
• Neutral Sentiment: Several firms maintained cautious views: HC Wainwright reaffirmed Neutral, Mizuho assigned Neutral, and Laidlaw reaffirmed Hold. These ratings indicate limited conviction in a near-term recovery following the clinical setback. HC Wainwright rating Mizuho rating Laidlaw rating
• Neutral Sentiment: Large call-option activity suggests some traders are positioning for a rebound, but options activity is speculative and does not change the company’s fundamental outlook. EyePoint call options
• Negative Sentiment: HC Wainwright reduced its Q3 2026 EPS estimate to a loss of $0.85 from $0.60 and cut its FY2026 estimate to a loss of $3.40 from $3.15, reflecting worsening near-term expectations. Revised EPS estimates
• Negative Sentiment: JPMorgan issued an Underweight rating, while Jefferies and Guggenheim downgraded the stock, adding further institutional pressure after the failed LUCIA trial. JPMorgan rating Jefferies downgrade Guggenheim downgrade
• Negative Sentiment: Levi & Korsinsky announced an investigation into potential securities claims related to the LUCIA trial disclosure and the resulting shareholder losses. The investigation adds legal and reputational risk, although it does not establish wrongdoing. Levi & Korsinsky investigation

About Eyepoint Pharmaceuticals

EyePoint Pharmaceuticals, Inc is a biopharmaceutical company focused on developing and commercializing therapies for serious eye diseases. The company specializes in sustained-release drug delivery technologies designed to provide extended treatment in the eye and potentially reduce the frequency of injections or other interventions.

EyePoint’s commercial products include YUTIQ, an intravitreal implant that delivers fluocinolone acetonide for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye, and DEXYCU, an intraocular suspension of dexamethasone used to treat postoperative inflammation following ocular surgery.